Roche Holding Ltd. (ROG) Stock Rating Reaffirmed by J P Morgan Chase & Co
Several other equities analysts also recently commented on the company. Morgan Stanley set a CHF 260 price target on Roche Holding and gave the company a neutral rating in a report on Friday, October 6th. Deutsche Bank AG set a CHF 258 price target on Roche Holding and gave the company a neutral rating in a report on Wednesday, October 4th. Goldman Sachs Group, Inc. (The) set a CHF 325 price target on Roche Holding and gave the company a buy rating in a report on Monday, October 2nd. BNP Paribas set a CHF 235 price target on Roche Holding and gave the company a sell rating in a report on Monday, September 25th. Finally, Jefferies Group LLC set a CHF 290 price target on Roche Holding and gave the company a buy rating in a report on Thursday, September 21st. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of CHF 267.73.
Roche Holding (ROG) opened at 244.90 on Monday. Roche Holding has a 52-week low of CHK 218.30 and a 52-week high of CHK 273.00. The firm has a market capitalization of CHK 208.96 billion and a PE ratio of 21.74. The stock’s 50 day moving average is CHK 244.83 and its 200-day moving average is CHK 251.39.
ILLEGAL ACTIVITY WARNING: “Roche Holding Ltd. (ROG) Stock Rating Reaffirmed by J P Morgan Chase & Co” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/10/13/roche-holding-ltd-rog-stock-rating-reaffirmed-by-j-p-morgan-chase-co.html.
About Roche Holding
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Stock Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related stocks with our FREE daily email newsletter.